Asset
INSULIN LISPRO
Eli Lilly and Company Common Stock
Revenue
| Period | Revenue |
|---|---|
| Q4 2024 | $619.9M |
| Q3 2024 | $534.6M |
| Q2 2024 | $631.6M |
| Q1 2024 | $538.7M |
| Q4 2023 | $366.6M |
| Q3 2023 | $395.4M |
| Q2 2023 | $440.4M |
| Q1 2023 | $460.9M |
| Q4 2022 | $548.3M |
| Q3 2022 | $447.0M |
Revenue as reported by this company. A combination product's amount appears on each of its constituent assets, so those figures are not additive. A fourth quarter is the reported full year less nine months, since no filing states one.
Clinical trials (59)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03341299 | phase1 | completed | 2017-11-13 | 2018-04-03 | Eli Lilly and Company | A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 1 Diabetes Mellitus |
| NCT03341312 | phase1 | completed | 2017-11-13 | 2018-03-31 | Eli Lilly and Company | A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM) |
| NCT03286751 | phase1 | completed | 2017-10-13 | 2018-02-06 | Eli Lilly and Company | A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants |
| NCT00666718 | phase3 | completed | 2008-04-01 | 2010-02-01 | Eli Lilly and Company | A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients |
| NCT03449433 | phase1 | completed | 2018-03-15 | 2018-08-14 | Eli Lilly and Company | A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus |
FDA applications (2)
| Application | Approved | Type | Applicant |
|---|---|---|---|
| BLA 205747 | 2015-05-26 | BLA | Eli Lilly and Company |
| BLA 020563 | 1996-06-14 | BLA | Eli Lilly and Company |
Marketed products (8)
- HUMALOG
- HUMALOG KWIKPEN
- HUMALOG KWIKPEN
- HUMALOG KWIKPEN
- HUMALOG PEN
- HUMALOG TEMPO PEN
- Humalog
- Humalog